We are live on ! Find out more
DTC

Deep Track Capital Portfolio holdings

AUM $6.12B
1-Year Est. Return 144%
This Fund
S&P 500
This Quarter Est. Return
-15.82%
1 Year Est. Return
+144%
3 Year Est. Return
+348.41%
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$1.52B
AUM Growth
-$38.2M
Cap. Flow
+$313M
Cap. Flow %
20.59%
Top 10 Hldgs %
48.92%
Holding
59
New
7
Increased
23
Reduced
11
Closed
8

Top Buys

Rank Stock Value
1
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$52.1M
2
NUVB icon
Nuvation Bio
NUVB
+$45M
3
GBT
Global Blood Therapeutics, Inc.
GBT
+$39.3M
4
ACAD icon
Acadia Pharmaceuticals
ACAD
+$32.3M
5
NRIX icon
Nurix Therapeutics
NRIX
+$27.6M

Top Sells

Rank Stock Value
1
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$65.8M
2
KROS icon
Keros Therapeutics
KROS
+$28.1M
3
SAGE
Sage Therapeutics
SAGE
+$16.9M
4
ENTA icon
Enanta Pharmaceuticals
ENTA
+$14.1M
5
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$9.75M

Sector Composition

Rank Sector Weight
1 Healthcare 95.07%
2 Real Estate 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GBT
1
DELISTED
Global Blood Therapeutics, Inc.
GBT
$117M 7.66%
3,646,690
+1,342,007
+58% +$39.3M
NVCR icon
2
NovoCure
NVCR
$1.77B
$93.2M 6.13%
1,341,300
+341,300
+34% +$25.7M
TVTX icon
3
Travere Therapeutics
TVTX
$5.12B
$86.8M 5.7%
3,580,700
+446,197
+14% +$11.2M
JAZZ icon
4
Jazz Pharmaceuticals
JAZZ
$16.1B
$78M 5.13%
500,000
-17,051
-3% -$2.62M
ALNY icon
5
CALL
Alnylam Pharmaceuticals
ALNY
$38.1B
$72.9M 4.79%
+499,900
New +$70.9M
KURA icon
6
Kura Oncology
KURA
$784M
$67.8M 4.46%
3,697,969
+285,969
+8% +$4.11M
MDGL icon
7
Madrigal Pharmaceuticals
MDGL
$12.4B
$64.8M 4.26%
905,000
+119,000
+15% +$8.75M
KDNY
8
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$60M 3.94%
3,430,110
+430,110
+14% +$6.75M
BMRN icon
9
BioMarin Pharmaceuticals
BMRN
$11.9B
$54.2M 3.56%
+654,365
New +$52.1M
FATE icon
10
Fate Therapeutics
FATE
$267M
$50M 3.29%
2,018,005
+18,005
+0.9% +$497K
BCYC
11
Bicycle Therapeutics
BCYC
$269M
$48.7M 3.2%
2,900,000
+1,044,007
+56% +$22M
BEAM icon
12
Beam Therapeutics
BEAM
$2.67B
$48.4M 3.18%
1,250,000
+486,250
+64% +$19.3M
ISEE
13
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$43.3M 2.85%
4,500,000
– –
AGEN
14
Agenus
AGEN
$279M
$43.1M 2.84%
1,133,200
+419,977
+59% +$15.2M
ESPR
15
DELISTED
Esperion Therapeutics
ESPR
$38.2M 2.51%
6,000,000
– –
RPTX
16
DELISTED
Repare Therapeutics
RPTX
$37.9M 2.49%
2,707,662
+43,645
+2% +$514K
NUVB icon
17
Nuvation Bio
NUVB
$2.26B
$37.2M 2.44%
11,471,281
+10,315,789
+893% +$45M
IMVT icon
18
Immunovant
IMVT
$7.8B
$36.9M 2.42%
9,455,000
+2,230,387
+31% +$9.63M
NKTX icon
19
Nkarta
NKTX
$150M
$34.7M 2.28%
2,814,844
+701,049
+33% +$9.2M
NRIX icon
20
Nurix Therapeutics
NRIX
$2.43B
$30.9M 2.03%
+2,436,164
New +$27.6M
FMTX
21
DELISTED
Forma Therapeutics Holdings, Inc. Common Stock
FMTX
$27.9M 1.83%
4,050,000
+2,390,294
+144% +$16.8M
TCDA
22
DELISTED
Tricida, Inc. Common Stock
TCDA
$26.4M 1.74%
2,732,117
+79,424
+3% +$756K
ACAD icon
23
Acadia Pharmaceuticals
ACAD
$4.46B
$24.4M 1.61%
+1,733,130
New +$32.3M
DYN icon
24
Dyne Therapeutics
DYN
$4.1B
$24M 1.58%
3,500,000
– –
FDMT icon
25
4D Molecular Therapeutics
FDMT
$495M
$21.9M 1.44%
3,140,000
+691,800
+28% +$6.73M
1
2 3

Similar funds

AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.13B AUM 23.41% 1-Year Est. Return
ACM
AKRE Capital Management Middleburg, Virginia $6.13B AUM 15.27% 1-Year Est. Return
CIS
Capital International Sarl Los Angeles, California $6.11B AUM 32.29% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return
JWBC
John W. Bristol & Co New York $6.08B AUM 16.51% 1-Year Est. Return
EMPI
Elo Mutual Pension Insurance Espoo, Finland $6.06B AUM 24.33% 1-Year Est. Return
HPG
Harvest Portfolios Group Oakville, Ontario, Canada $6.06B AUM 16.63% 1-Year Est. Return
B
Barings Charlotte, North Carolina $6.19B AUM 16.5% 1-Year Est. Return

Deep Track Capital's Q2 2022 Portfolio in Review

As of Q2 2022, Deep Track Capital held 59 positions worth $1.52B, down 2.4% from $1.56B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

Deep Track Capital deployed $313M of net new capital in Q2 2022, opening 7 new positions and adding to 23 existing holdings. Its largest new stake was BioMarin Pharmaceuticals: 654,365 shares worth $54.2M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, down from 99% a quarter earlier, followed by Real Estate.

On the sell side, the largest reduction was Keros Therapeutics, an estimated $28.1M trimmed.

  • Deep Track Capital's largest Q2 2022 buy was BioMarin Pharmaceuticals: 654,365 shares worth $54.2M.
  • Deep Track Capital added most to Nuvation Bio in Q2 2022, an estimated $45M increase.
  • Deep Track Capital's biggest Q2 2022 reduction was Keros Therapeutics, cutting an estimated $28.1M.
  • Deep Track Capital fully exited Alnylam Pharmaceuticals in Q2 2022, selling an estimated $65.8M.
  • Deep Track Capital's ten largest holdings make up 49% of its $1.52B portfolio in Q2 2022.
  • Deep Track Capital opened 7 new positions and closed 8 in Q2 2022.
  • Deep Track Capital's portfolio value fell 2.4% quarter-over-quarter to $1.52B.

Based on Deep Track Capital's 13F filing for Q2 2022, filed 12 Aug 2022.